Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
1. A compound of formula (I):
wherein:
R 1 is furanyl, wherein said furanyl may be optionally substituted with alkyl, alkoxy, halo or —CN;
R a is H or alkyl;
R b is H or alkyl;
or R a and R b together with the atom to which they are attached form a 3 to 8 membered saturated or partially saturated hydrocarbon ring or form a 4 to 8 membered saturated or partially saturated heterocyclic ring comprising a ring member selected from O, N(R 3 ) and S;
R 2 is H, alkyl or heterocycloalkyl, wherein said alkyl may optionally be substituted with halo, alkoxy or heterocycloalkyl;
provided that R 2 is selected from heterocycloalkyl and alkyl substituted by halo, alkoxy or heterocycloalkyl, when R 1 is furan-2-yl or 5-methyl-furan-2-yl and R a and R b are both H; and
R 3 is H or alkyl; and
wherein:
heteroaryl is a 5 or 6 membered aromatic ring, comprising one or two ring members selected from N, N(R 4 ), S and O;
alkyl (or the alkyl group of the alkoxy group) is a linear or branched saturated hydrocarbon containing up to 10 carbon atoms;
heterocycloalkyl is a C-linked or N-linked 3 to 10 membered non-aromatic, monocyclic ring, wherein said heterocycloalkyl ring comprises 1, 2 or 3 ring members independently selected from N, N(R 4 ), S(O) q and O;
R 4 is H or alkyl; and
q is 0, 1 or 2;
or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein R 1 is 2-furanyl and wherein said 2-furanyl may be optionally substituted with alkyl or alkoxy.
3. The compound of claim 1 , wherein R a and R b together with the atom to which they are attached form a tetrahydropyryl ring, a cyclobutyl ring, a cyclopentyl ring, or a cyclohexyl ring.
4. The compound of claim 1 , wherein R a and R b are independently selected from H and (C 1 -C 6 )alkyl.
5. The compound of claim 1 , wherein R a and R b are independently selected from H and methyl.
6. The compound of claim 1 , wherein R a and R b are H.
7. The compound of claim 2 , wherein R a and R b are H.
8. The compound of claim 1 , wherein R 2 is selected from H, (C 1 -C 4 )alkyl and tetrahydrofuranyl, wherein said (C 1 -C 4 )alkyl may optionally be substituted with fluoro, (C 1 -C 3 )alkoxy and tetrahydrofuranyl.
9. The compound of claim 1 , wherein R 2 is selected from H and tetrahydrofuranyl.
10. The compound of claim 1 , wherein R 2 is tetrahydrofuranyl.
11. The compound of claim 2 , wherein R 2 is tetrahydrofuranyl.
12. The compound of claim 6 , wherein R 2 is tetrahydrofuranyl.
13. The compound of claim 7 , wherein R 2 is tetrahydrofuranyl.
14. The compound of claim 6 , wherein R 1 is 5-methyl-furan-2-yl.
15. The compound of claim 10 , wherein R 1 is 5-methyl-furan-2-yl.
16. The compound of claim 12 , wherein R 1 is 5-methyl-furan-2-yl.
17. The compound of claim 1 , having the formula:
S-7-(5-methylfuran-2-yl)-3-(6-[tetrahydrofuran-3-yl]oxymethylpyrid-2-ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof.
18. A pharmaceutical composition comprising: (a) a pharmaceutically acceptable carrier and (b) a compound of claim 1 or a pharmaceutically acceptable salt thereof.
19. A pharmaceutical composition comprising: (a) a pharmaceutically acceptable carrier and (b) a compound of claim 16 or a pharmaceutically acceptable salt thereof.
20. A pharmaceutical composition comprising: (a) a pharmaceutically acceptable carrier and (b) a compound of claim 17 or a pharmaceutically acceptable salt thereof.